A drug binds a receptor with very high affinity but produces no biological response at all. This drug's intrinsic activity is best described as:
Choose an answer, then check it.
Clinical Pharmacology · Pharmacodynamics
Agonists and Antagonists
On this page 6 sections
In 30 seconds
Once a drug binds its receptor, two separate properties decide what happens next: affinity (how tightly it binds) and intrinsic activity (what it does once bound). Agonists activate the receptor — fully, partially, or even in reverse — while antagonists block activation without triggering a response themselves. Whether more agonist can "outcompete" an antagonist depends entirely on how that antagonist attaches: reversibly at the same site, or irreversibly, or at a separate allosteric site. This one distinction explains why naloxone reverses an opioid overdose, why buprenorphine can precipitate opioid withdrawal, and why a patient on a beta-blocker may need extra epinephrine during anaphylaxis.
The college version
Affinity and Intrinsic Activity
Every drug-receptor interaction has two independent dimensions. Affinity is the strength of attraction between a drug and its receptor — how readily it binds and how long it stays bound. Intrinsic activity is the capacity of that bound drug to change the receptor's shape and trigger a biological response. A drug can have high affinity with zero intrinsic activity (a pure antagonist), high affinity with full intrinsic activity (a full agonist), or high affinity with only partial intrinsic activity (a partial agonist). Affinity determines whether a drug binds at all; intrinsic activity determines what happens after it does. Two drugs can bind the same receptor equally well and produce completely different outcomes because their intrinsic activity differs.
Full, Partial, and Inverse Agonists
A full agonist binds the receptor and produces the maximum response the receptor system can generate, once enough receptors are occupied. Morphine at the mu-opioid receptor is a familiar example, producing maximal analgesic signaling.
A partial agonist binds the same receptor but produces a submaximal response even when every receptor is occupied — its intrinsic activity is less than a full agonist's. Buprenorphine, used to treat opioid use disorder, is a mu-receptor partial agonist: it activates the receptor enough to relieve craving and withdrawal, but with a ceiling on effects like respiratory depression, making it safer than a full agonist. A clinically important consequence follows directly from this: giving a partial agonist to a patient already saturated with a full agonist can precipitate withdrawal, because the partial agonist displaces the full agonist from the receptor while supplying less activation than the receptor was getting before.
Some receptors show a baseline level of activity even with nothing bound, called constitutive activity. An inverse agonist binds these receptors and pushes activity below that baseline — it doesn't merely fail to activate, it actively suppresses signaling. This differs from a neutral antagonist, which occupies the receptor, blocks other ligands, but leaves baseline activity unchanged. Many drugs once classified simply as antagonists have since been reclassified as inverse agonists once constitutive activity was recognized.
Competitive vs. Noncompetitive Antagonism
A competitive antagonist binds reversibly at the same active site the agonist uses. Because the binding is reversible and both molecules compete for one site, raising the agonist concentration can displace the antagonist and restore the full response — this shifts the agonist's dose-response curve rightward without lowering its maximum achievable effect. This is why naloxone can reverse an opioid overdose, and also why the reversal can wear off before the opioid does, sometimes requiring repeat dosing.
A noncompetitive antagonist lowers the maximum achievable response no matter how much agonist is added. This happens in two ways: irreversible binding at the same active site, often through a strong bond that does not dissociate, or binding at a separate allosteric site that distorts the receptor so the agonist cannot activate it even while still attached. Either way, adding more agonist cannot restore full effect, because the affected receptors are permanently disabled or functionally uncoupled from their response. Restoring function typically requires the body to synthesize new receptor protein rather than simply clearing more drug.
Chemical and Physiologic Antagonism
Not all antagonism happens at a shared receptor. Chemical antagonism occurs when one substance directly binds and inactivates another independent of any receptor system — protamine sulfate neutralizing heparin is the standard teaching example. Physiologic (functional) antagonism occurs when two agonists act at entirely different receptors to produce opposite effects on the same physiological outcome, such as one pathway raising heart rate while another lowers it. Beta-blockade is the clinical workhorse example of ordinary competitive receptor antagonism: propranolol competitively blocks beta receptors, so a large enough dose of a beta-agonist like epinephrine can still partially overcome that blockade — one reason anaphylaxis in a patient taking a beta-blocker sometimes calls for higher or repeated epinephrine dosing.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of a receptor like a doorbell button, and a drug like a finger pressing it. A full agonist pushes the button all the way in, and the bell rings as loud as it can. A partial agonist only pushes it halfway, so you get a quiet ring even if every finger available is pressing at once. An inverse agonist is weirder: imagine the doorbell already hums faintly by itself, and this "finger" presses in a way that makes the hum stop entirely.
An antagonist doesn't press the button at all — it just sits on it so nobody else can press it either. Now, how it sits matters a lot. A competitive antagonist is like a finger resting lightly on the button: if enough other fingers crowd in and push harder, they can nudge it aside and ring the bell anyway. A noncompetitive antagonist is like someone gluing gum over the button, or jamming the wire behind it — no matter how many fingers push, nothing rings until someone replaces the button.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient who took an opioid overdose is given naloxone and improves, but two hours later becomes sedated and has slowed breathing again. Using what you know about competitive antagonism, explain why this can happen.
Show answer
Naloxone wears off faster than many opioids stay in the body
Naloxone is a competitive antagonist that temporarily wins the tug-of-war at the receptor, but it doesn't last as long as some opioids do. As naloxone's effect fades, remaining opioid molecules are still around to re-occupy the receptors, so sedation and respiratory depression can return, which is why repeat dosing or monitoring is often needed.
A patient taking a nonselective beta-blocker develops anaphylaxis, and the treating clinician anticipates needing a higher-than-usual dose of epinephrine. Explain the receptor-level reason for this in one or two sentences.
Show answer
Beta-blockade is competitive, so enough epinephrine can still get through
Because a beta-blocker like propranolol occupies the beta receptor reversibly and competes with agonists for the same site, giving a large enough dose of epinephrine can still displace some of the blocker and activate enough receptors to help reverse anaphylaxis, even though the blockade blunts the usual response.
Quick check
3 questions here. Answers stay hidden until you check.
A patient stabilized on a full mu-opioid agonist is given buprenorphine, a partial agonist, and develops sudden withdrawal symptoms. The most likely explanation is that buprenorphine:
Choose an answer, then check it.
Which property allows a competitive antagonist's effect to be reversed simply by giving more agonist, while an irreversible antagonist's effect cannot be reversed this way?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.